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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a progressive
loss of the corticospinal tract, brainstem, and spinal neurons, leading to progressive muscle atrophy
and weakness, and ultimately to death due to respiratory failure.
The right to be informed is enshrined in the European Oviedo Convention (Council of Europe,
1997). The Awaji diagnostic criteria for ALS are generally used, identifying definite, probable,
possible and suspected ALS (de Carvalho et al., 2008).Moreover, the pathway of a correct diagnostic
assessment of ALS needs a complex algorithm of knowledge. There are no biochemical markers that
allow a definitive diagnosis, and the clinical knowledge of the general practitioner in the early stages
is critical in order to direct the patient to the neurologist.
Psychological Assessment
Emotions have not often been studied in ALS. Most existing studies have assessed the
psychopathological manifestations involved, essentially depression Ferentinos et al. (2011) and less
frequently anxiety. The results have shown that major depressive episodes and anxious episodes
are not frequent in ALS patients, although moderate depressive or anxious symptoms are often
observed, but less frequently than in other diseases such as multiple sclerosis or Parkinson’s disease
(Pagnini, 2013).
Patients and their families experience the period of diagnostic assessment for possible ALS with
anxiety and distress. When this period is extended, the risk of developing depressive symptoms is
greater (Caga et al., 2014). Moreover, a higher prevalence of depression is expected in patients
with more severe ALS (Pagnini et al., 2012). In ALS cohorts 7% have minor depression, and
5% have current major depressive disorder (Rabkin et al., 2014). Further, depressive symptoms
are significantly related to poorer quality of life (Pizzimenti et al., 2013). A recent study found
no correlation between the severity of depression and anxiety and ALS Functional Rating Scale-
Revised (ALSFRS-R) score or for disease duration in ALS patients (Chen et al., 2015). However,
another investigation of emotional states measured using the Hospital Anxiety and Depression
Scale (HADS) showed worsening depression and anxiety scores as ALS progressed (Jones et al.,
2014). A recent longitudinal study on “wishing to die” and depression in ALS shows that “wishing
to die” is not always expressed in the context of a state of depression and does not necessarily denote
psychopathology as such (Rabkin et al., 2014). It is iportant to note that ALS can also be associated
not only with psychological problems but also with the impairment of many neuropsychological
functions.
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Comorbidity with FTD
ALS and FTD could be two ends of the spectrum of one
disease (Taes et al., 2010). Approximately 15% of ALS patients
show Fronto-Temporal Dementia (FTD) with TDP43 positive
inclusions in cortical neurons, whereas at least 50% of them
evidence subtle cognitive and/or behavioral dysfunction (Lillo
and Hodges, 2009; Lillo et al., 2014). Patients with clinical
evidence for both disorders have ALS-FTD. Furthermore, many
patients with ALS show some cognitive or behavioral changes
without meeting the criteria for FTD; they are described as ALS
with cognitive or behavioral impairment (ALS-Ci/Bi). Patients
with FTD can similarly show evidence of mild motor neuron
involvement without developing ALS: they are said to have
FTD-MND.
A significant delay in the time-course of selective attentive
processing and a difficulty in initiating and sustaining attention
may be present in ALS-b, which points to the possibility of
dysfunction in the frontal neural network that responds to
novelty and to abnormal integration of associative functions.
This attentional impairment should be taken into account
when developing alternative communicative strategies in ALS
patients (Mannarelli et al., 2014). Although FTD patients
exhibit prominent deficits in emotion perception and social
cognition, these domains have received relatively little attention
in ALS. Performance on emotion processing tasks may provide
a useful clinical tool in identifying patients with early FTD-ALS
(Savage et al., 2014). Structural and functional neuroimaging
have demonstrated that ALS is associated with abnormalities
localized mainly in the frontal lobes, and neuropathological
investigations have shown the pathological involvement of the
prefrontal cortex (Troakes et al., 2012). In FTD structural brain
imaging and neuropsychological data involve the functions of
the prefrontal cortex. Damage to this region is associated with
deficient performance in theory ofmind and in affective decision-
making, but the relationship between these two capacities
in patients with prefrontal cortex dysfunction is unclear.
Further neuropsychological or functional studies are indicated
as necessary to improve early identification of patients affected
by FTD. Comorbidity with FTD should be considered where
ALS is diagnosed, and importantly, also when this diagnosis is
communicated to patients.
When, What, and How to Communicate
Diagnosis
ALS is a deadly disease. The appropriate ways to communicate
the diagnosis to patients could be similar to the strategies used in
other serious pathologies, such as some variations of cancers with
short survival rates.
If ALS is associated with FTD, both diagnoses should be
communicated to patients. In this regard the evidence base
of good practice in the communication of dementia diagnoses
may also be useful for FTD-ALS. For example, in managing
newly diagnosed ALS patients, physicians need to consider the
following questions: “when, what, and how to communicate the
diagnosis?”
When to Communicate the Diagnosis?
The communication of the diagnosis is a complex event:
it contains “informative,” “prognostic,” and “therapeutic”
components. The “informative” component or phase provides
and defines factual information regarding the medical condition.
The “prognostic” component describes the short and long-
term implications for the patient and family. The therapeutic
component consists of the proposal of a practical plan for
management (Karnieli-Miller et al., 2007). In ALS the time of
the communication of the diagnosis will often coincide with the
communication of prognosis and therapy. The time taken for the
informative component is generally shorter than for the other
components, which could be reflective of the discomfort of the
physician in delivering bad news.
The difficulties for the medical team in making a diagnosis
of ALS, and in the moment of communication of the
diagnosis to patients has been reported in a recent study
(Schellenberg et al., 2014). Physicians and other healthcare
workers should learn and implement effective methods for
delivering information on the patient’s health status (Marcus and
Mott, 2014).
The communication process must consider:
– The creation of a strong therapeutic alliance between the
entire multidisciplinary team and the patient. A good alliance
is critical to subsequent discussion of treatment options
(Back et al., 2009). Only within a relationship of reciprocal
confidence and trust can the communication of a disease
like ALS be understood and processed by the patient. The
psychologist is crucial to the creation of this alliance (Marcus
and Mott, 2014).
– The comorbidity with FTD and the stage of disease. If
the progression of dementia is fast, the communication of
diagnosis should be earlier. The diagnosis of FTD and ALS
should be communicated when the patient is still able to
understand it and to choose his/her own future strategies to
cope with his/her illness in accordance with national laws.
– The comorbidity with depression, taking psychological
support into account, using measures of risk of suicide. Suicide
risk does not exempt the physician from the communication of
the diagnosis at a more opportune time.
– The psychological support to the patient and caregiver before
and after communication of diagnosis (Miller et al., 2009).
What to Communicate?
The communication about prognosis and evolution in ALS
is complicated by the variability of the clinical course and
the possible psychopathological and neurological comorbidities.
Moreover, patients with ALS-FTD can have increased difficulties
with, or lack cognitive resources for, decision-making. In all
forms of dementia, despite its importance and implications, the
format, content and process of this communication has received
insignificant research attention.
The communication should be patient centered and include:
– A clear description of diagnosis, prognosis and therapeutic
choices. A truthful but compassionate communication
between physicians and patients is essential for decisions
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about both disease-directed (curative) and palliative therapies
(Rich, 2014).
– Feedback of the patient’s understanding about his/her
knowledge and acceptance of the disease. This is very
important in the case of FTD. The FTD would present
impaired anosognosia-related implicit awareness due to a
dysfunctional implicit integration of contextual information
caused by an abnormal fronto-insular-temporal network
(Ibáñez et al., 2013). In FTD, the inhibition, self-monitoring,
set-shifting, and mood orientation changes appear to be
important skills for awareness of instrumental activities of
daily living, while hypo manic mood orientation and a
tendency for apathy to be prominent are indications of reduced
behavioral awareness (Amanzio et al., 2013).
– The monitoring of the awareness of the patient at the time.
Some elderly patients can refuse to receive information about
their illness and can abdicate to the paternalistic model of
medicine, while other patients tend to search all possible
avenues for information. In a survey in Germany 28% of
patients and 23% of caregivers used (alternative) resources
to find information related to their symptoms before seeing
a doctor, mainly from the internet. After the medical visit,
although two-thirds were satisfied with the means-disclosure
of diagnosis, 88% of patients and 85% of caregivers searched
for additional information, most often online and by reading
brochures from patients’ associations (Abdulla et al., 2014).
– The presence of relatives or caregivers, only if it is accepted by
the patient.
How to Communicate the Diagnosis?
Communication of ALS diagnosis may be psychologically
traumatic, and patients may need to cope with this by using
defense mechanisms as well as individual resources such as
resilience. Generally physicians may be unprepared to break
bad news, mostly because of a lack of training in emotional
management (Pagnini et al., 2012). The relationship between
the communication of a negative diagnosis and the response
of the patients will depend to a great extent on the manner
in which the message is transmitted, but to our knowledge
these aspects have been poorly studied in motor neuron
diseases.
The method of communicating a diagnosis of ALS should
include:
– The application of techniques of counseling, including a
comfortable space, adequate time for processing information,
respect for the patient and his/her reactions, acceptance of the
patient’s reactions.
– The possibility of countertransference: the individual health
professional should pay particular attention to his or her
personal emotions, such as feelings about death.
– Existing evidence based knowledge of methods of
communication, for example the Six-Step Protocol for
Delivering Bad News used in cancer care (Kaplan, 2010).
This includes: setting up the interview, assessing the
patient’s perception, obtaining the patient’s invitation, giving
knowledge and information to the patient, addressing the
patient’s emotions with empathic responses, strategy, and
summary.
– The use of simple words that can be understood easily by the
patient. The use of euphemisms, vague words, and not naming
the disease could be a defense mechanism of the physician
(Karnieli-Miller et al., 2007).
In conclusion, communicating a diagnosis of ALS should be
done in a way that empowers patients and caregivers in order to
improve the disease management and decisions about treatment
options. To be effective, it should be individualized, by taking into
account several features including:
(a) Stage of the disease at the moment of the diagnosis and
possible cognitive impairment;.
(b) Personal characteristics (including personality traits,
personal values, possible psychopathological complications
like depressive phenomena and mood liability);.
(c) Social and cultural environment of the patient and his/her
family, in order to harmonize the communicative process
with the values and cultural aspects of the family.
Being part of the medical team and involved from the very
beginning in all phases of the healing process, by supporting
physicians in their role, the psychologist can prove to be helpful
in enhancing it indirectly, as well as directly supporting patients
and caregivers.
References
Abdulla, S., Vielhaber, S., Machts, J., Heinze, H. J., Dengler, R., and Petri, S. (2014).
Information needs and information-seeking preferences of ALS patients and
their careers. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 505–512.
doi: 10.3109/21678421.2014.932385
Amanzio, M., Vase, L., Leotta, D., Miceli, R., Palermo, S., and Geminiani, G.
(2013). Impaired awareness of deficits in Alzheimer’s disease: the role of
everyday executive dysfunction. J. Int. Neuropsychol. Soc. 19, 63–72. doi:
10.1017/S1355617712000896
Back, A., Arnold, R., and Tulsky, J. (2009). Mastering Communication with
Seriously Ill Patients. New York, NY: Cambridge University Press.
Caga, J., Ramsey, E., Hogden, A., Mioshi, E., and Kiernan, M. C. (2014). A longer
diagnostic interval is a risk for depression in amyotrophic lateral sclerosis.
Palliat. Support. Care 19, 1–6. doi: 10.1017/S1478951514000881
Chen, D., Guo, X., Zheng, Z., Wei, Q., Song, W., and Cao, B. (2015). Depression
and anxiety in amyotrophic lateral sclerosis: correlations between the distress
of patients and caregivers.Muscle Nerve 51, 353–357. doi: 10.1002/mus.24325
Council of Europe. (1997). Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on Human
Rights and Biomedicine. Oviedo, 4.IV.1997. Available online at:
http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm
de Carvalho, M., Dengler, R., Eisen, A., England, J. D., Kaji, R., Kimura, J., et al.
(2008). Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 119,
497–503. doi: 10.1016/j.clinph.2007.09.143
Ferentinos, P., Paparrigopoulos, T., Rentzos, M., Zouvelou, V., Alexakis, T., and
Evdokimidis, I. (2011). Prevalence of major depression in ALS: comparison of
a semi-structured interview and four self-report measures. Amyotroph. Lateral
Scler. 12, 297–302. doi: 10.3109/17482968.2011.556744
Frontiers in Psychology | www.frontiersin.org 3 June 2015 | Volume 6 | Article 745
Pizzimenti et al. Communication of ALS diagnosis
Ibáñez, A., Velásquez, M. M., Caro, M. M., and Manes, F. (2013). Implicit
emotional awareness in frontotemporal dementia. Cogn. Neurosci. 4, 204–206.
doi: 10.1080/17588928.2013.854756
Jones, A. R., Jivraj, N., Balendra, R., Murphy, C., Kelly, J., and Thornhill, M. (2014).
Health utility decreases with increasing clinical stage in amyotrophic lateral
sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 215, 285–291. doi:
10.3109/21678421.2013.872149
Kaplan, M. (2010). SPIKES: a framework for breaking bad news to patients with
cancer. Clin. J. Oncol. Nurs. 14, 514–516. doi: 10.1188/10.CJON.514-516
Karnieli-Miller, O., Werner, P., Aharon-Peretz, J., and Eidelman, S. (2007).
Dilemmas in the (un)veiling of the diagnosis of Alzheimer’s disease: walking
an ethical and professional tight rope. Patient Educ. Couns. 67, 307–314. doi:
10.1016/j.pec.2007.03.014
Lillo, P., and Hodges, J. R. (2009). Frontotemporal dementia and motor
neuron disease: overlapping clinic-pathological disorders. J. Clin. Neurosci. 16,
1131–1135. doi: 10.1016/j.jocn.2009.03.005
Lillo, P., Matamala, J. M., Valenzuela, D., Verdugo, R., Castillo, J. L., Ibáñez,
A., et al. (2014). Overlapping features of frontotemporal dementia and
amyotrophic lateral sclerosis. Rev. Med. Chil. 142, 867–879. doi: 10.4067/S0034-
98872014000700007
Mannarelli, D., Pauletti, C., Locuratolo, N., Vanacore, N., Frasca, V.,
Trebbastoni, A., et al. (2014). Attentional processing in bulbar- and
spinal-onset amyotrophic lateral sclerosis: insights from event-related
potentials. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 30–38. doi:
10.3109/21678421.2013.787628
Marcus, J. D., and Mott, F. E. (2014). Difficult conversations: from diagnosis to
death. Ochsner J. 14, 712–717.
Miller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston,
W., et al. (2009). Practice parameter update: the care of the patient with
amyotrophic lateral sclerosis: multidisciplinary care, symptom management,
and cognitive/behavioral impairment (an evidence-based review): report of
the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology 73, 1227–1233. doi: 10.1212/WNL.0b013e3181bc01a4
Pagnini, F. (2013). Psychological weelbeing and quality of life in
amyotrophic lateral sclerosis: a review. Int. J. Psychol. 48, 194–205. doi:
10.1080/00207594.2012.691977
Pagnini, F., Simmons, Z., Corbo, M., and Molinari, E. (2012). Amyotrophic lateral
sclerosis: time for research on psychological intervention? Amyotroph. Lateral
Scler. 13, 416–417. doi: 10.3109/17482968.2011.653572
Pizzimenti, A., Aragona, M., Onesti, E., and Inghilleri, M. (2013). Depression,
pain and quality of life in patients with amyotrophic lateral sclerosis: a
cross-sectional study. Funct. Neurol. 28, 115–119. doi: 10.11138/FNeur/2013.
28.2.115
Rabkin, J. G., Goetz, R., Factor-Litvak, P., Hupf, J., McElhiney, M., Singleton,
J., et al. (2014). Depression and wish to die in a multicenter cohort of
ALS patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 8, 1–9. doi:
10.3109/21678421.2014.980428
Rich, B. A. (2014). Prognosis terminal: truth-telling in the context of end-of-life
care. Camb. Q. Healthc. Ethics 23, 209–219. doi: 10.1017/S0963180113000741
Savage, S. A., Lillo, P., Kumfor, F., Kiernan, M. C., Piguet, O., and Hodges,
J. R. (2014). Emotion processing deficits distinguish pure amyotrophic
lateral sclerosis from frontotemporal dementia. Amyotroph. Lateral Scler.
Frontotemporal Degener. 15, 39–46. doi: 10.3109/21678421.2013.809763
Schellenberg, K. L., Schofield, S. J., Fang, S., and Johnston, W. S. (2014).
Breaking bad news in amyotrophic lateral sclerosis: the need for medical
education. Amyotroph Lateral SclerFrontotemporal Degener. 15, 47–54. doi:
10.3109/21678421.2013.843711
Taes, I., Goris, A., Lemmens, R., van Es, M. A., van den Berg, L. H.,
and Chio, A. (2010). Tau levels do not influence human ALS or motor
neuron degeneration in the SOD1G93A mouse. Neurology 74, 1687–1693. doi:
10.1212/WNL.0b013e3181e042f7
Troakes, C., Maekawa, S., Wijesekera, L., Rogelj, B., Siklós, L., Bell, C., et al. (2012).
An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant
p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus
and cerebellum but without associated cognitive decline. Neuropathology 32,
505–514. doi: 10.1111/j.1440-1789.2011.01286.x
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Pizzimenti, Gori, Onesti, John and Inghilleri. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Psychology | www.frontiersin.org 4 June 2015 | Volume 6 | Article 745
